The effects of favipiravir on hematological parameters of covıd-19 patients

Yaylacı, Selçuk; Dheir, Hamad; Şenocak, Didar; Genç, Ahmed Bilal; Kocayiğit, Havva; Çekiç, Deniz; Varım, Ceyhun; Aydın, Abdülkadir; Köroğlu, Mehmet; Karabay, Oğuz

doi:10.1590/1806-9282.66.s2.65

Cited by 18 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the 11 studies, three studies were RCTs [16,[18][19][20], one study was a non-randomized controlled study [17], one study was a before and after nonrandomized controlled study [21], and six studies were observational studies or case series [22][23][24][25][26]. Among the comparative studies, the comparators included umifenovir [17], baloxavir marboxil [18], standard of care (SOC) [19], lopinavir/ritonavir [21], and HQ alone or in combination with azithromycin [25].…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited. Methods We conducted a systematic review of published studies reporting the efficacy of favipiravir against COVID-19. Two investigators independently searched PubMed, the Cochrane Database of Systematic Reviews, MedRxiv, and ClinicalTrials.gov (inception to September 2020) to identify eligible studies. A meta-analysis was performed to measure viral clearance and clinical improvement as the primary outcomes. Results Among 11 eligible studies, 5 included a comparator group. Comparing to the comparator group, the favipiravir group exhibited significantly better viral clearance on day 7 after the initiation of treatment (odds ratio [OR] = 2.49, 95% confidence interval [CI] = 1.19–5.22), whereas no difference was noted on day 14 (OR = 2.19, 95% CI = 0.69–6.95). Although clinical improvement was significantly better in the favipiravir group on both days 7 and 14, the improvement was better on day 14 (OR = 3.03, 95% CI = 1.17–7.80) than on day 7 (OR = 1.60, 95% CI = 1.03–2.49). The estimated proportions of patients with viral clearance in the favipiravir arm on days 7 and 14 were 65.42 and 88.9%, respectively, versus 43.42 and 78.79%, respectively, in the comparator group. The estimated proportions of patients with clinical improvement on days 7 and 14 in the favipiravir group were 54.33 and 84.63%, respectively, compared with 34.40 and 65.77%, respectively, in the comparator group. Conclusions Favipiravir induces viral clearance by 7 days and contributes to clinical improvement within 14 days. The results indicated that favipiravir has strong possibility for treating COVID-19, especially in patients with mild-to-moderate illness. Additional well-designed studies, including examinations of the dose and duration of treatment, are crucial for reaching definitive conclusions.

show abstract

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to the same study, although the white blood cell count did not change after taking favipiravir, the platelet count increased significantly. 14 In this study, anaemia was observed in 16.2%, neutropenia in 3.5% and thrombocytopenia in 2.6% of patients after favipiravir treatment.…”

Section: Discussionmentioning

confidence: 50%

The safety profile of favipiravir in COVID‐19 patients with severe renal impairment

Gök

Bahçecíoğlu

Durmuş

et al. 2021

Int J Clinical Practice

View full text Add to dashboard Cite

Objective The safety profile of favipiravir in patients with severe renal impairment has not been investigated and available data are insufficient. The study aimed to compare the incidence of favipiravir‐associated adverse events amongst patients with varying renal function statuses. Methods Records of 921 patients who were hospitalised for COVID‐19 and had received at least 5 days of favipiravir treatment were retrospectively evaluated and 228 patients were included in the study. Patients’ age, sex, comorbidities, estimated glomerular filtration rate (eGFR) and haematological and biochemical values were recorded. The incidence of adverse events was compared with the age, sex, comorbidities and eGFR of the patients. Results The mean age of the patients was 59.3 ± 15.6 years, and 38.2% of the patients were women. One hundred and thirty‐one (57.5%) patients had experienced adverse events. These adverse effects consisted of ALT elevation (35.5%), AST elevation (21.5%), anaemia (16.2%), hyperuricaemia (10.5%), hepatocellular injury (9.2%), neutropenia (3.5%) and thrombocytopenia (2.6%). The incidence of adverse events was not significantly different when patients had eGFR >60 mL/min/1.73 m 2 or eGFR 30‐60 mL/min/1.73 m 2 ( P > .05), but significantly increased when the eGFR dropped to <30 ( P < .05). The differences seen with hyperuricaemia and anaemia were significant ( P < .05). Conclusion Even though favipiravir appeared to be well tolerated in the individuals with renal failure in this study, its use in this population remains a challenge that requires more research and analysis.

show abstract

“…We recently showed that the using of standardized dose of FVP for five days reduced the erythroid series as side effects in a small study involving 62 COVID-19 positive patients (22). Also, FVP related hyperuricemia was reported previously (23).…”

Section: Discussionmentioning

confidence: 60%

Şiddetli COVID-19 Pnömonisinde Favipiravir Tedavisinin Etkinliği: Tek Merkez Deneyimi

Dheir

Yaylacı

Sipahi

et al. 2021

Konuralp Tıp Dergisi

Self Cite

View full text Add to dashboard Cite

The aim of this study was to investigate the efficacy of favipiravir (FVP) in severe . Methods: This is a retrospective study of 142 COVID-19 patients with severe pneumonia signs, who received inpatient treatment between March 15 and May 20, 2020. The patients were divided into two groups according to the use of FVP treatment; group 1 (n = 99) included patients who treated with FVP and group 2 (n = 43) who didn't receive FVP. Results: Mean age was 66.47 ± 11.89 in group 1, and 68.58 ± 14.78 in group 2. Forty patients (40.4%) in group 1 and 22 (51.2%) in group 2 were treated in the intensive care unit (P > 0.05). The proportion of eosinophil, tendency of increasing thrombocyte counts and eosinophil/neutrophil ratio in FVP group was significantly higher than non-FVP group (p < 0.05). In Group 1, patients had significantly reduced erythroid series, and elevated uric acid levels as side effects of FVP. With respect to complications during hospitalization, there was no significant difference among the groups for mechanical ventilator requirement, acute kidney injury, dialysis requirement and sepsis (P > 0.05). The mortality rates in Group 1 (n = 26 [26.3%]) were lower than those in group 2 (n = 16 [37.2%]), but it was not statistically significant. Conclusions: While the treatment of COVID-19 pneumonia options were limited during the initial stages of the pandemic, the FVP may be effective in severe cases. To confirm this effect, randomized controlled studies are needed in patients of all disease severities.

show abstract

The effects of favipiravir on hematological parameters of covıd-19 patients

Cited by 18 publications

References 17 publications

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis

The safety profile of favipiravir in COVID‐19 patients with severe renal impairment

Şiddetli COVID-19 Pnömonisinde Favipiravir Tedavisinin Etkinliği: Tek Merkez Deneyimi

Contact Info

Product

Resources

About